This review outlines the molecular mechanisms of P2Y1 and P2Y12 receptors in platelet aggregation and their importance as targets for antiplatelet therapies.
Answers are grounded in this paper and cite their sources.
Reinforces dual P2Y1/P2Y12 targeting in antiplatelet strategies; leaves open clinical development of selective ADP analogues.
With the cloning of the P2Y12 receptor, the molecular basis for ADP-induced platelet aggregation is seemingly complete. Two platelet-bound ADP receptors, P2Y1 and P2Y12, operate through unique pathways to induce and sustain platelet aggregation via the glycoprotein (GP)IIb-IIIa integrin. P2Y1 operates via a glycoprotein q (Gq) pathway, activates phospholipase C, induces platelet shape change and is responsible for intracellular calcium mobilisation. P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo). In addition, the receptor is targeted by the ADP analogue AR-C66096, which is currently in Phase IIb clinical trials, as well as other non-nucleoside-based preclinical leads.
No takes yet. Share an insight, caveat, or question.
Shawn M. Bauer (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: